UIC-2018-090 and UIC-2018-077 – Novel Nicotinamide Phosphoribosyltransferase Inhibitors as Potential Therapeutics for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery).10,000 to 20,000 patients live with this disease in the US and Approximately 500-1000 new cases of PAH are diagnosed each year in the U.S.The exact cause of PAH is unknown and although treatable, there is no known cure for the disease. UIC Solution How: UIC inventors identified a cytozyme – nicotinamide phosphoribosyltransferase (NAMPT) – that presents elevated levels in patients suffering from PAH and contributes to pulmonary vascular remodeling What: UIC inventors propose two series of compounds as novel NAMPT enzyme inhibitors to treat PAH. Why: These compounds were screened and found to exhibit in vitro NAMPT inhibition with IC50 values as low as 26 nM in CycLex colormetric assay Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More